Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 48: 1145-1146, 2002;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (3)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Diamandis, E. P.
Right arrow Articles by Bruns, D. E.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Diamandis, E. P.
Right arrow Articles by Bruns, D. E.
Related Collections
Right arrow Cancer Diagnostics (since 2002)
(Clinical Chemistry. 2002;48:1145-1146.)
© 2002 American Association for Clinical Chemistry, Inc.

Introduction

Cancer Diagnostics: Discovery and Clinical Applications—Introduction

Eleftherios P. Diamandis1 and David E. Bruns2

1 Special Issue Editor, Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, 600 University Ave., Toronto, Ontario, M5G 1X5 Canada

2 Editor, Department of Pathology, University of Virginia Health Sciences Center, Box 214, Charlottesville, VA 22908

The first 20% of the full text of this article appears below.

Tumor marker analysis constitutes a sizable portion of routine clinical chemistry testing. This area of investigation has advanced considerably over the last 50 years. Many new tumor markers have been discovered and are now used routinely for cancer screening, diagnosis, and monitoring and for prediction of therapeutic response. Despite these advances, it is clear that the contribution of these markers to patient care and, especially, to altering clinical outcomes is relatively limited. Most, if not all, of the markers that we use today are compromised by their low diagnostic sensitivity and specificity. The nature of cancer as a disease is such that it is not acceptable to misdiagnose or mistreat patients. For this reason, tumor markers are not used for definitive diagnosis; they are used as aids to help physicians make decisions, after combining other clinical and diagnostic data.

Recent advances in the field . . . [Full Text of this Article]




The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
E. P. Diamandis
Proteomic Patterns in Biological Fluids: Do They Represent the Future of Cancer Diagnostics?
Clin. Chem., August 1, 2003; 49(8): 1272 - 1275.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the American Association for Clinical Chemistry.